- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jennifer Malin Predicts Biosimilars Will Have Little Impact on Treatment Costs
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
The introduction of biosimilars into the US market will not have a large impact on treatment costs until the volume of biosimiliars for different therapies increases, predicted Jennifer Malin, MD, medical director for oncology at Anthem.
She added that biosimilars are still expensive to produce and will therefore not have the same impact as generics do in relation to costs.
“The challenge is just that in the face of biosimilars, we also have newer molecules that are coming out that are more effective in some cases than the older versions that now have biosimilars available,” Dr Malin said.
KEYNOTE-905 Paves the Way for Next Generation of MIBC Trials: Christof Vulsteke, MD, PhD
October 20th 2025Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.
Read More
